Published online 22 September 2009
Haematologica, Vol 95, Issue 1, 135-143 doi:10.3324/haematol.2008.001628
Copyright © 2010 by Ferrata Storti Foundation

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Lim, S. H. Articles by Cragg, M. S. PubMed PubMed Citation Articles by Lim, S. H. Articles by Cragg, M. S.

Malignant Lymphomas

Anti-CD20 monoclonal antibodies: historical and future perspectives

Sean H. Lim, Stephen A. Beers, Ruth R. French, Peter W.M. Johnson, Martin J. Glennie, Mark S. Cragg

Tenovus Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, UK

Correspondence: Mark S Cragg, Tenovus Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, SO16 6YD, UK. E-mail: msc{at}soton.ac.uk

Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced.

Key words: CD20, monoclonal antibodies, lymphoma, immunotherapy.

This article has been cited by other articles:

				S. A. Beers, M. S. Cragg, and M. J. Glennie Complement: help or hindrance? Blood, December 24, 2009; 114(27): 5567 - 5568. [Full Text] [PDF]

				M. Introna and J. Golay Complement in antibody therapy: friend or foe? Blood, December 17, 2009; 114(26): 5247 - 5248. [Full Text] [PDF]